Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of “Buy” from Brokerages

Immuneering Co. (NASDAQ:IMRXGet Rating) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $29.13.

A number of research firms have recently weighed in on IMRX. Zacks Investment Research raised shares of Immuneering from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday. Oppenheimer began coverage on shares of Immuneering in a research note on Thursday, March 31st. They issued an “outperform” rating and a $25.00 price target on the stock.

In other news, Director Ann E. Berman purchased 6,000 shares of the firm’s stock in a transaction on Tuesday, March 15th. The stock was bought at an average cost of $6.40 per share, for a total transaction of $38,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 9,900 shares of company stock valued at $69,201 over the last 90 days.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMRX. UBS Group AG bought a new stake in shares of Immuneering in the third quarter valued at about $30,000. Citigroup Inc. bought a new stake in shares of Immuneering in the third quarter valued at about $33,000. New York State Common Retirement Fund bought a new stake in shares of Immuneering in the third quarter valued at about $45,000. Metropolitan Life Insurance Co NY bought a new stake in shares of Immuneering in the third quarter valued at about $75,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Immuneering by 119.5% in the first quarter. JPMorgan Chase & Co. now owns 11,969 shares of the company’s stock valued at $78,000 after buying an additional 6,515 shares during the period. Institutional investors and hedge funds own 47.41% of the company’s stock.

Shares of NASDAQ:IMRX opened at $4.42 on Thursday. Immuneering has a 12-month low of $4.11 and a 12-month high of $33.99. The company’s fifty day moving average is $6.44 and its two-hundred day moving average is $13.79.

Immuneering (NASDAQ:IMRXGet Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.60 million. On average, sell-side analysts forecast that Immuneering will post -2.01 earnings per share for the current fiscal year.

Immuneering Company Profile (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Read More

Analyst Recommendations for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.